Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE)

American Heart Journal

Volumn 178, Issue , 2016, Pages 198-205

  DeVore, Adam D ^a,b   Greiner, Melissa A ^a   Sharma, Puza P ^c   Qualls, Laura G ^a   Schulte, Phillip J ^d   Cooper, Lauren B ^a,b   Mentz, Robert J ^a,b   Pang, Peter S ^e   Fonarow, Gregg C ^f   Curtis, Lesley H ^a,b   Hernandez, Adrian F ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MAYO CLINIC   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INOTROPIC AGENT; SODIUM; TROPONIN;

ACUTE HEART FAILURE; AGED; ARTICLE; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DISEASE EXACERBATION; DRUG DOSE ESCALATION; FEMALE; GROUPS BY AGE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; IN HOSPITAL WORSENING HEART FAILURE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICARE; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ACUTE DISEASE; AGE; BLOOD; BLOOD PRESSURE; DISEASE COURSE; HEART STROKE VOLUME; HOSPITALIZATION; INFORMATION RETRIEVAL; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; REGISTER; RISK ASSESSMENT; STATISTICAL MODEL; UNITED STATES; VALIDATION STUDY; VERY ELDERLY;

ACUTE DISEASE; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOMARKERS; BLOOD PRESSURE; CREATININE; DISEASE PROGRESSION; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INFORMATION STORAGE AND RETRIEVAL; LOGISTIC MODELS; MALE; MEDICARE; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; REGISTRIES; RISK ASSESSMENT; STROKE VOLUME; TROPONIN; UNITED STATES;

EID: 84989313035     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2016.04.021     Document Type: Article

References (41)

1. 1 Pfuntner, A., Stocks, C., Most frequent conditions in U.S. hospitals, 2011. HCUP statistical brief #162. September 2013. 2013, Agency for Healthcare Research and Quality, Rockville, MD [http://www.hcup-us.ahrq.gov/reports/statbriefs/sb148.pdf. Accessed June 5, 2015].
2. 2 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–e322.
3. 3 Center for Medicare & Medicaid Services, Medicare hospital quality chartbook: performance report on outcome measures. http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/Downloads/Medicare-Hospital-Quality-Chartbook-2014.pdf, 2014 [Accessed June 5, 2015].
4. 4 Chen, J., Normand, S.L., Wang, Y., et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA 306 (2011), 1669–1678.
5. 5 Loehr, L.R., Rosamond, W.D., Chang, P.P., et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 101 (2008), 1016–1022.
6. 6 McMurray, J.J., Teerlink, J.R., Cotter, G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298 (2007), 2009–2019.
7. 7 Massie, B.M., O'Connor, C.M., Metra, M., et al. Rolofylline, an adenosine a1-receptor antagonist, in acute heart failure. N Engl J Med 363 (2010), 1419–1428.
8. 8 Hernandez, A.F., O'Connor, C.M., Starling, R.C., et al. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). Am Heart J 157 (2009), 271–277.
9. 9 Packer, M., Colucci, W., Fisher, L., et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 1 (2013), 103–111.
10. 10 Teerlink, J.R., Cotter, G., Davison, B.A., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381 (2013), 29–39.
11. 11 DeVore, A.D., Hammill, B.G., Sharma, P.P., et al. In‐hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. J Am Heart Assoc 3:4 (2014), 1–11.
12. 12 Torre-Amione, G., Milo-Cotter, O., Kaluski, E., et al. Early worsening heart failure in patients admitted for acute heart failure: time course, hemodynamic predictors, and outcome. J Card Fail 15 (2009), 639–644.
13. 13 Cotter, G., Metra, M., Weatherley, B.D., et al. Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure—association with signs and symptoms, hospitalization duration, and 60-day outcomes. Cardiology 115 (2010), 29–36.
14. 14 Cotter, G., Metra, M., Davison, B.A., et al. Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. Eur J Heart Fail 16 (2014), 1362–1371.
15. 15 Davison, B.A., Metra, M., Cotter, G., et al. Worsening heart failure following admission for acute heart failure: a pooled analysis of the PROTECT and RELAX-AHF studies. JACC Heart Fail 3 (2015), 395–403.
16. 16 Cooper, L.B., Hammill, B.G., Sharma, P.P., et al. Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. Am Heart J 170:6 (2015), 1124–1132.
17. 17 Fonarow, G.C., The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 4:Suppl. 7 (2003), S21–S30.
18. 18 Adams, K.F. Jr., Fonarow, G.C., Emerman, C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005), 209–216.
19. 19 Hammill, B.G., Hernandez, A.F., Peterson, E.D., et al. Linking inpatient clinical registry data to medicare claims data using indirect identifiers. Am Heart J 157 (2009), 995–1000.
20. 20 Peacock, W.F., De Marco, T., Fonarow, G.C., et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 358 (2008), 2117–2126.
21. 21 Harrell, F.E. Jr., Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. 2001, Springer-Verlag, New York, NY.
22. 22 Krumholz, H.M., Wang, Y., Mattera, J.A., et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 113 (2006), 1693–1701.
23. 23 O'Connor, C.M., Mentz, R.J., Cotter, G., et al. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. Eur J Heart Fail 14 (2012), 605–612.
24. 24 Vittinghoff, E., Glidden, D.V., Shiboski, S.C., et al. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. 2012, Springer, New York, NY.
25. 25 Harrell, F.E. Jr., Lee, K.L., Mark, D.B., Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996), 361–387.
26. 26 Steyerberg, E.W., Clinical prediction models: a practical approach to development, validation, and updating. 2009, Springer, New York, NY.
27. 27 Vergouwe, Y., Steyerberg, E.W., Eijkemans, M.J., et al. Validity of prognostic models: when is a model clinically useful?. Semin Urol Oncol 20 (2002), 96–107.
28. 28 Hosmer, D.W. Jr., Lemeshow, S., Sturdivant, R.X., Applied logistic regression. 2013, John Wiley & Sons Inc.
29. 29 Shahian, D.M., O'Brien, S.M., Filardo, G., et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1—coronary artery bypass grafting surgery. Ann Thorac Surg 88 (2009), S2–S22.
30. 30 Meenan, R.T., O'Keeffe-Rosetti, C., Hornbrook, M.C., et al. The sensitivity and specificity of forecasting high-cost users of medical care. Med Care 37 (1999), 815–823.
31. 31 Hosmer, D.W., Lemesbow, S., Goodness of fit tests for the multiple logistic regression model. Commun Stat Theory Methods 9 (1980), 1043–1069.
32. 32 Swedberg, K., Adams, K.F., Anker, S.D., et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365 (2011), 32–43.
33. 33 Weatherley, B.D., Cotter, G., Dittrich, H.C., et al. Design and rationale of the protect study: a placebo-controlled randomized study of the selective a1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 16 (2010), 25–35.
34. 34 Teerlink, J.R., McMurray, J.J., Bourge, R.C., et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Study (VERITAS). Am Heart J 150 (2005), 46–53.
35. 35 Ponikowski, P., Metra, M., Teerlink, J.R., et al. Design of the relaxin in acute heart failure study. Am Heart J, 163, 2012 [149-155.e141].
36. 36 Ramirez, A., Abelmann, W.H., Cardiac decompensation. N Engl J Med 290 (1974), 499–501.
37. 37 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 128 (2013), e240–e327.
38. 38 Tendera, M., Torbicki, A., Vahanian, A., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14 (2012), 803–869.
39. 39 Felker, G.M., Butler, J., Collins, S.P., et al. Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor: rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). JACC Heart Fail 3 (2015), 193–201.
40. 40 Efficacy and safety of ularitide for the treatment of acute decompensated heart failure (TRUE-AHF). https://clinicaltrials.gov/ct2/show/NCT01661634 [Accessed June 5, 2015].
41. 41 Kociol, R.D., Hammill, B.G., Fonarow, G.C., et al. Generalizability and longitudinal outcomes of a national heart failure clinical registry: comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. Am Heart J 160 (2010), 885–892.